RECRUITINGOBSERVATIONAL
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration
About This Trial
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Who May Be Eligible (Plain English)
Who May Qualify:
- Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records
- Best-corrected visual acuity between 20/70 and HM in at least one eye as tested with clinic-based visual acuity method
- Reasonably fluent in English
Who Should NOT Join This Trial:
- Cognitive impairment, memory loss or dementia sufficient in severity to preclude willing to sign a consent form or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
- Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
- Current pregnancy as reported by patient
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records
* Best-corrected visual acuity between 20/70 and HM in at least one eye as tested with clinic-based visual acuity method
* Reasonably fluent in English
Exclusion Criteria:
* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
* Current pregnancy as reported by patient
Locations (1)
Vision Research and Assessment Institute
Irvine, California, United States